<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03529110</url>
  </required_header>
  <id_info>
    <org_study_id>DS8201-A-U302</org_study_id>
    <secondary_id>2018-000222-61</secondary_id>
    <nct_id>NCT03529110</nct_id>
  </id_info>
  <brief_title>DS-8201a Versus T-DM1 for Human Epidermal Growth Factor Receptor 2 (HER2)-Positive, Unresectable and/or Metastatic Breast Cancer Previously Treated With Trastuzumab and Taxane</brief_title>
  <official_title>A Phase 3, Multicenter, Randomized, Open-Label, Active-Controlled Study of DS-8201a (Trastuzumab Deruxtecan), an Anti-HER2 Antibody Drug Conjugate (ADC), Versus Ado Trastuzumab Emtansine (T-DM1) for HER2-Positive, Unresectable and/or Metastatic Breast Cancer Subjects Previously Treated With Trastuzumab and Taxane</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Daiichi Sankyo, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Daiichi Sankyo Co., Ltd.</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Daiichi Sankyo, Inc.</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study is designed to compare the anti-tumor activity as well as the safety and efficacy
      of DS-8201a versus T-DM1 in HER2-positive, unresectable and/or metastatic breast cancer
      subjects previously treated with trastuzumab and taxane.
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">August 10, 2018</start_date>
  <completion_date type="Anticipated">February 2022</completion_date>
  <primary_completion_date type="Anticipated">February 2022</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Progression-free survival (PFS) based on blinded independent central review (BICR)</measure>
    <time_frame>Within 45 months</time_frame>
    <description>Time from the date of randomization to the earliest date of the first objective documentation of radiographic disease progression via BICR according to RECIST version 1.1 or death due to any cause</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Overall survival (OS)</measure>
    <time_frame>At 45 months</time_frame>
    <description>Time from the date of randomization to the date of death for any cause. If there is no death reported for a subject before the data cutoff for OS analysis, OS will be censored at the last contact date at which the subject is known to be alive</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Objective response rate (ORR) based on BICR and investigator's assessment</measure>
    <time_frame>Within 45 months</time_frame>
    <description>Percentage of participants with complete response (CR) and partial response (PR) based on BICR and based on investigator assessment</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Duration of response (DoR) based on BICR and investigator's assessment</measure>
    <time_frame>Within 45 months</time_frame>
    <description>Length of time response continued based on BICR and investigator's assessment</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Clinical benefit rate (CBR)</measure>
    <time_frame>Within 45 months</time_frame>
    <description>Percentage of participants receiving clinical benefit from the treatment based on BICR and investigator's assessment</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Progression-free survival (PFS) based on investigator's assessment</measure>
    <time_frame>Within 45 months</time_frame>
    <description>PFS based on investigator's assessment is time from the date of randomization to the earliest date of the first objective documentation of radiographic disease progression via investigator-assessed disease progression according to RECIST version 1.1 or death due to any cause</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">500</enrollment>
  <condition>Breast Cancer</condition>
  <arm_group>
    <arm_group_label>Trastuzumab deruxtecan (DS-8201a)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>HER2-positive, unresectable and/or metastatic breast cancer participants previously treated with trastuzumab and taxane randomized to treatment with DS-8201a</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Ado-trastuzumab emtansine (T-DM1)</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>HER2-positive, unresectable and/or metastatic breast cancer participants previously treated with trastuzumab and taxane randomized to treatment with T-DM1</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Trastuzumab deruxtecan (DS-8201a)</intervention_name>
    <description>DS-8201a is sterile lyophilized powder reconstituted into a sterile aqueous solution (100 mg/5 mL) to be administered intravenously</description>
    <arm_group_label>Trastuzumab deruxtecan (DS-8201a)</arm_group_label>
    <other_name>DS-8201a</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ado-trastuzumab emtansine (T-DM1)</intervention_name>
    <description>The treatment will be in accordance with the approved label</description>
    <arm_group_label>Ado-trastuzumab emtansine (T-DM1)</arm_group_label>
    <other_name>T-DM1</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Is the age of majority in their country

          -  Has pathologically documented breast cancer that is unresectable or metastatic

          -  Has confirmed HER2-positive expression as determined according to American Society of
             Clinical Oncology - College of American Pathologists guidelines, evaluated at a
             central laboratory

          -  Was previously treated with trastuzumab and taxane in the advanced/metastatic setting
             or progressed within 6 months after neoadjuvant or adjuvant treatment involving a
             regimen including trastuzumab and taxane

          -  Has documented radiologic progression (during or after most recent treatment or within
             6 months after completing adjuvant therapy)

          -  Has an adequate tumor sample available for confirmation of HER2 status by Central
             Laboratory (based on most recent tumor tissue sample)

          -  If of reproductive/childbearing potential, agrees to use a highly effective form of
             contraception or avoid intercourse during and upon completion of the study, and for at
             least 4 months after the

          -  Has adequate hematopoietic, renal and hepatic functions

        Exclusion Criteria:

          -  Has uncontrolled or significant cardiovascular disease

          -  Has a history of (noninfectious) interstitial lung disease (ILD)/pneumonitis that
             required steroids, has current ILD/pneumonitis, or where suspected ILD/pneumonitis
             cannot be ruled out by imaging at screening

          -  Has active central nervous system (CNS) metastases
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Global Team Leader</last_name>
    <role>Study Director</role>
    <affiliation>Daiichi Sankyo, Inc.</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>(For Sites in Asia Only) Daiichi Sankyo Contact for Clinical Trial Information</last_name>
    <phone>+81-3-6225-1111(M-F 9-5 JST)</phone>
    <email>dsclinicaltrial@daiichisankyo.co.jp</email>
  </overall_contact>
  <verification_date>May 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>April 13, 2018</study_first_submitted>
  <study_first_submitted_qc>May 7, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">May 18, 2018</study_first_posted>
  <last_update_submitted>May 24, 2018</last_update_submitted>
  <last_update_submitted_qc>May 24, 2018</last_update_submitted_qc>
  <last_update_posted type="Estimate">May 28, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Breast Cancer</keyword>
  <keyword>Metastatic breast cancer</keyword>
  <keyword>DS-8201a</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Breast Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Taxane</mesh_term>
    <mesh_term>Ado-trastuzumab emtansine</mesh_term>
    <mesh_term>Trastuzumab</mesh_term>
    <mesh_term>Maytansine</mesh_term>
    <mesh_term>Camptothecin</mesh_term>
    <mesh_term>Immunoconjugates</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>De-identified individual participant data (IPD) and applicable supporting clinical trial documents may be available upon request at https://www.clinicalstudydatarequest.com//. In cases where clinical trial data and supporting documents are provided pursuant to our company policies and procedures, Daiichi Sankyo will continue to protect the privacy of our clinical trial participants. Details on data sharing criteria and the procedure for requesting access can be found at this web address: https://www.clinicalstudydatarequest.com/Study-Sponsors/Study-Sponsors-DS.aspx</ipd_description>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

